Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
Age ≥ 18 years old and ≤ 75 years old at the time of randomization.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Expected life expectancy of at least 3 months.
Histologically or cytologically confirmed diagnosis of NSCLC.
Locally advanced or metastatic NSCLC (American Joint Committee on Cancer \[AJCC\] 8th edition).
Previously received systemic platinum-based chemotherapy and PD-1/L1 inhibitors.
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Adequate organ function.

Histologic or cytopathologic evidence of the presence of small cell lung carcinoma.
Other malignancies within 3 years prior to randomization.
Known actionable genomic alterations.
Prior administration of any immunotherapy targeting immune mechanisms other than PD-1/PD-L1 inhibitors.
Previous treatment with docetaxel.
History of severe bleeding tendency or coagulation dysfunction.
Active autoimmune disease requiring systemic therapy within 2 years prior to randomization.
History of myocarditis, cardiomyopathy, and malignant arrhythmia.

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer